Tumor targeting by an aptamer

Journal of Nuclear Medicine

Volumn 47, Issue 4, 2006, Pages 668-678

  Hicke, Brian J ^a,c   Stephens, Andrew W ^a   Gould, Ty ^a   Chang, Ying Fon ^a   Lynott, Cynthia K ^a   Heil, James ^a   Borkowski, Sandra ^b   Hilger, Christoph Stephan ^b   Cook, Gary ^a   Warren, Stephen ^a   Schmidt, Paul G ^a  

^a GILEAD SCIENCES   (United States)

^b BAYER PHARMA AG   (Germany)

^c Global Technologies (NZ) Ltd   (New Zealand)

Author keywords

Extracellular matrix; Imaging; Oligonucleotide; SELEX; Tenascin C

Indexed keywords

APTAMER; CHELATING AGENT; MACROGOL; MACROGOL 3400; MERCAPTOACETYLDIGLYCINE; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; RHODAMINE; TENASCIN; TTA1 TC 99M; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DIPEPTIDE; FLUORESCENT DYE; ORGANOMETALLIC COMPOUND; TECHNETIUM 99M MERCAPTO ACETYL DIGLYCINE; TECHNETIUM 99M MERCAPTO-ACETYL DIGLYCINE; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG HALF LIFE; FEMALE; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; SCINTIGRAPHY; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; EXPERIMENTAL NEOPLASM; HUMAN; METABOLISM; NUDE MOUSE; PROTEIN BINDING; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; CHELATING AGENTS; DIPEPTIDES; FEMALE; FLUORESCENT DYES; HUMANS; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ORGANOMETALLIC COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PENTETIC ACID; PROTEIN BINDING; RADIOPHARMACEUTICALS; RHODAMINES; TENASCIN; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 33745108827     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Wu AM, Chen W, Raubitschek A, et al. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology. 1996;2:21-36.
2. Adams GP, Schier R, McCall AM, et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human her2/neu. Br J Cancer. 1998;77:1405-1412.
3. 99mTc. Q J Nucl Med. 1996;40:221-233.
4. Boerman OC, Kranenborg MH, Oosterwijk E, et al. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res. 1999;59:4400-4405.
5. Paganelli G, Grana C, Chinol M, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med. 1999;26:348-357.
6. Gold L, Polisky B, Uhlenbeck O, Yarus M. Diversity of oligonucleotide functions. Annu Rev Biochem. 1995;64:763-797.
7. Famulok M, Mayer G. Aptamers as tools in molecular biology and immunology. Curr Top Microbiol Immunol. 1999;243:123-136.
8. Watson SR, Chang YF, O'Connell D, Weigand L, Ringquist S, Parma DH. Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. Antisense Nucleic Acid Drug Dev. 2000;10:63-75.
9. Ruckman J, Green LS, Beeson J, et al. 2′-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem. 1998;273:20556-20567.
10. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for sufoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology. 2003;110:979-986.
11. Guhlke S, Famulok M, Biersack HJ. Aptamares: a novel class of radiopharmaceutical with diagnostic and therapeutic potential. Eur J Nucl Med Mol Imaging. 2003;30:1441-1443.
12. Hicke BJ, Stephens AW. Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest. 2000;106:923-928.
13. Cerchia L, Hamm J, Libri D, Tavitian B, de Franciscis V. Nucleic acid aptamers in cancer medicine. FEBS Lett. 2002;528:12-16.
14. Charlton J, Sennello J, Smith D. In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol. 1997;4:809-816.
15. 3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled antisense DNA. Eur J Nucl Med. 2000;27:1700-1707.
16. Tavitian B, Terrazzino S, Kuhnast B, et al. In vivo imaging of oligonucleotides with positron emission tomography. Nat Med. 1998;4:467-471.
17. Hicke BJ, Marion C, Chang YF, et al. Tenascin-c aptamers are generated using tumor cells and purified protein. J Biol Chem. 2001;276:48644- 48654.
18. Zagzag D, Friedlander DR, Miller DC, et al. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res. 1995;55:907-914.
19. Erickson HP, Bourdon MA. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol. 1989;5:71-92.
20. Koukoulis GK, Gould VE, Bhattacharyya A, Gould JE, Howeedy AA, Virtanen I. Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Hum Pathol. 1991;22:636-643.
21. Mackie EJ, Halfter W, Liverani D. Induction of tenascin in healing wounds. J Cell Biol. 1988;107:2757-2767.
22. Wallner K, Li C, Shah PK, et al. Tenascin-c is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation. 1999;99:1284-1289.
23. Lightner VA, Slemp CA, Erickson HP. Localization and quantitation of hexabrachion (tenascin) in skin, embryonic brain, tumors, and plasma. Ann N Y Acad Sci. 1990;580:260-275.
24. Lastoria S, Castelli L, Vergara E, et al. Human gliomas radioimmunoimaging with 131-I BC-2 murine IgG: preliminary report. J Nucl Med Allied Sci. 1990;34:173-176.
25. 99mTc]PNAO-biotin. Eur J Nucl Med. 1994;21:314-321.
26. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-c aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A. 2003;100:15416-15421.
27. Green LS, Jellinek D, Bell C, et al. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol. 1995;2:683-695.
28. Hilger CS, Willis MC, Wolters M, Pieken WA. Tc-99m-labeling of modified RNA. Nucleosides Nucleotides. 1999;18:1479-1481.
29. Bridonneau P, Bunch S, Tengler R, et al. Purification of a highly modified RNA-aptamer: effect of complete denaturation during chromatography on product recovery and specific activity. J Chromatogr B Biomed Sci Appl. 1999;726:237-247.
30. Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, et al. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J Nucl Med. 1994;35:1054-1063.
31. Balza E, Siri A, Ponassi M, et al. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett. 1993;332:39-43.
32. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2, and Fab in tumors. Cancer Res. 1989;49:5656-5663.
33. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992;52:5144-5153.
34. 213Bi, and their decay chain related radionuclides, for therapeutic applications. Chem Rev. 2001;101:2019-2036.
35. Tarli L, Balza E, Viti F, et al. A high-affinity human antibody that targets tumoral blood vessels. Blood. 1999;94:192-198.
36. Borsi L, Carnemolla B, Nicolo G, Spina B, Tanara G, Zardi L. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer. 1992;52:688-692.
37. Healy JM, Lewis SD, Kurz M, et al. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res. 2004;21:2234-2246.
38. 111In-labeled DOTA-conjugated antibody fragments. Bioconjug Chem. 2001;12:264-270.
39. 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res. 1995;55:5714s-5720s.
40. Arano Y. Strategies to reduce renal radioactivity levels of antibody fragments. Q J Nucl Med. 1998;42:262-270.